-
Mashup Score: 15
Rashid Sayyid and Zach Klaassen discuss the 2023 amended AUA guidelines for advanced prostate cancer, focusing on metastatic hormone-sensitive prostate cancer (mHSPC). They emphasize the importance of assessing metastatic disease extent in newly diagnosed mHSPC patients, as it significantly influences systemic therapy choices. The guidelines recommend using either conventional imaging or PSMA…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1Analyzing mHSPC Patient Responses to ADT with Enzalutamide vs. Apalutamide - Benjamin Lowentritt - 2 month(s) ago
Benjamin Lowentritt discusses metastatic hormone-sensitive prostate cancer (mHSPC) patients’ responses to ADT combined with enzalutamide or apalutamide. Dr. Lowentritt explains the study’s methodology, emphasizing the importance of a deep and quick PSA response as a positive outcome marker. Initial findings suggest a faster and more prevalent PSA90 response in patients treated with apalutamide…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 2Sharing Care within Private Clinics for Patients with Newly Diagnosed mHSPC - David Morris & Benjamin Garmezy - 2 month(s) ago
Alicia Morgans hosts a multidisciplinary discussion with David Morris and Benjamin Garmezy focusing on the treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Morris highlights the increasing trend of referring patients with high-volume Gleason 8 disease and metastatic cancer to tertiary care centers. He emphasizes the importance of early discussions about…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Evolving strategies in #mHSPC Treatment! Join @CaPsurvivorship, David Morris, MD, FACS @tennesseeuro & @BGarmezy for insights into referral trends, therapy intensification, and private practice collaboration highlighting this dynamic landscape > https://t.co/AkZ3mOO2cy @BayerUS https://t.co/v7D3i6by7X
-
-
Mashup Score: 15
Rashid Sayyid and Zach Klaassen discuss the 2023 amended AUA guidelines for advanced prostate cancer, focusing on metastatic hormone-sensitive prostate cancer (mHSPC). They emphasize the importance of assessing metastatic disease extent in newly diagnosed mHSPC patients, as it significantly influences systemic therapy choices. The guidelines recommend using either conventional imaging or PSMA…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 9
Zach Klaassen is joined by Chandler Park and Ryan Malone to explore the collaborative approach between GU medical oncology and urology in managing metastatic hormone-sensitive prostate cancer with triplet therapy. Drs. Park and Malone, who met through shared patients and conferences, emphasize the importance of co-management in treating these complex cases. They discuss patient selection for…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 4Collaborating on Triplet Therapy for Metastatic Hormone-Sensitive Prostate Cancer - Daniel Saltzstein - 3 month(s) ago
Zach Klaassen converses with Daniel Saltzstein about the collaborative approach in treating metastatic hormone-sensitive prostate cancer with triplet therapy. Dr. Saltzstein describes their unique setup in San Antonio, where a medical oncologist is part of their urology team, facilitating seamless collaboration and treatment intensification. They focus on identifying high-volume, high-risk…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0Sharing Care within Private Clinics for Patients with Newly Diagnosed mHSPC - David Morris & Benjamin Garmezy - 3 month(s) ago
Alicia Morgans hosts a multidisciplinary discussion with David Morris and Benjamin Garmezy focusing on the treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Morris highlights the increasing trend of referring patients with high-volume Gleason 8 disease and metastatic cancer to tertiary care centers. He emphasizes the importance of early discussions about…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Evolving strategies in #mHSPC Treatment! Join @CaPsurvivorship, David Morris, MD, FACS @tennesseeuro & @BGarmezy for insights into referral trends, therapy intensification, and private practice collaboration highlighting this dynamic landscape > https://t.co/AkZ3mOO2cy @BayerUS https://t.co/v7D3i6by7X
-
-
Mashup Score: 14
Rashid Sayyid and Zach Klaassen discuss the 2023 amended AUA guidelines for advanced prostate cancer, focusing on metastatic hormone-sensitive prostate cancer (mHSPC). They emphasize the importance of assessing metastatic disease extent in newly diagnosed mHSPC patients, as it significantly influences systemic therapy choices. The guidelines recommend using either conventional imaging or PSMA…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 5A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in mHSPC: A-DREAM - Atish D. Choudhury - 6 month(s) ago
In a conversation between Alicia Morgans and Atish Choudhury, they discuss a study called A-DREAM that is examining the right balance of treatment duration for patients with metastatic prostate cancer. They note that androgen deprivation therapy (ADT) works well for many patients, but it can also lead to complications such as weight gain, muscle loss, and cardiovascular issues over time. To…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in mHSPC: A-DREAM - Atish D. Choudhury - 7 month(s) ago
In a conversation between Alicia Morgans and Atish Choudhury, they discuss a study called A-DREAM that is examining the right balance of treatment duration for patients with metastatic prostate cancer. They note that androgen deprivation therapy (ADT) works well for many patients, but it can also lead to complications such as weight gain, muscle loss, and cardiovascular issues over time. To…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
@AmerUrological guidelines provide a roadmap for assessing disease burden and personalizing systemic therapies in #mHSPC. @RKSayyid @UofT and @zklaassen_md @GACancerCenter discuss on UroToday > https://t.co/9LusjqaxZH https://t.co/IJaZjYy0Kc